What guidance did Lantern Pharma's management provide for the next earnings period?

What factors drove the changes in Lantern Pharma's revenue and profit?

What is Lantern Pharma's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Lantern Pharma year over year?

What is Lantern Pharma's gross profit margin?

What were the key takeaways from Lantern Pharma's earnings call?

Did Lantern Pharma beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Lantern Pharma next quarter?

- **Clinical Success**: LP-184 Phase Ia shows 48% clinical benefit rate; LP-300 achieves 86% response rate in never-smokers.
- **AI Breakthrough**: RADR modules deliver 94% BBB permeability accuracy; withZeta enables rapid rare cancer drug discovery.
- **Cash Runway**: $12.4M supports operations into Q3 2026; $1.6M raised via ATM in Q3.
- **Strategic Growth**: $7B+ addressable market for LP-184 trials; Zeta to transform rare cancer R&D with 500K+ trial insights.

**【CEO Summary Section】**
- **Clinical Milestones**: LP-184 Phase Ia trial achieved a 48% clinical benefit rate in evaluable patients, with notable tumor reductions in DNA damage repair mutation carriers. LP-300 showed an 86% clinical benefit rate in never-smoker lung cancer, including a 2-year complete response.
- **Pipeline Expansion**: LP-184 advancing into 4 Phase Ib/II trials targeting $7B+ market (triple-negative breast, NSCLC, bladder, GBM). LP-284 demonstrates complete responses in recurrent lymphomas and potential in autoimmune diseases.
- **AI Commercialization**: RADR AI modules (PredictBBB, LBx-AI) achieve 94% and 86-90% accuracy, with $1B+ market potential. New withZeta platform for rare cancer drug discovery launched, enabling rapid insights across 500K+ trials and 1.2M+ data points.
- **Operational Efficiency**: Transitioned CRO services in Asia to reduce costs, maintaining $12.4M cash runway into Q3 2026.

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: Net loss of $4.2M ($0.39/share), down 7% YoY. R&D expenses decreased 35% to $2.4M, G&A up 27% to $1.9M due to business development. Cash position of $12.4M supports operations into mid-2026.
- **Funding Updates**: Sold $1.6M in ATM shares Q3, with $634K raised post-quarter. Fully diluted shares: ~12.26M.

**【Q&A Highlights】**
- **Clinical Trial Timelines**: LP-300 interim data webinar in December; Denmark bladder cancer trial启动 late Dec/early Jan. IND submission for pediatric CNS trial expected soon.
- **Partnership Opportunities**: Interest from pharma companies in LP-184 Phase Ib/II trials; withZeta demos to partners in Q1 2026.
- **AI Platform Expansion**: Zeta已内部使用，计划Q1 2026全面推出，可加速罕见癌药物开发周期数月。


Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

LTRN

LTRN fundamentals

You can ask Aime